Building on the promising results of OBEMINALE 1, a confirmatory study – dubbed OBEMINALE 2 – was launched in 2018, aimed at obtaining an EFSA 13(5) health claim for Stablor® in 2020 and then licensing-out the product to a commercial partner
Bring the first drug based on the Christensenella minuta gut bacteria targeting obesity and metabolic disorders into the first clinical trial planned for 2020
Unlock the potential of the Christensenellaceae family of bacteria via our dedicated platform, in order to identify new therapeutic applications
Incubate and maturate microbiome-related exploratory projects likely to become new drug candidates to expand our pipeline
Microbiome & us
Nov 5, 2019
LNC Therapeutics Announces Formation of its Scientific Advisory Board |
Appoints international experts with...